Arlette Scheifes

Learn More
BACKGROUND Psychotropic drugs are prescribed to approximately 30-40% of adults with intellectual disability (ID) and challenging behaviour, despite the limited evidence of effectiveness and the potential of adverse events. AIMS To assess the prevalence of adverse events in association with psychotropic drug use in adults with ID and challenging behaviour(More)
BACKGROUND Antipsychotic drugs are prescribed to approximately 30% to 40% of adults with intellectual disability (ID) and behavioral problems despite lack of evidence of effectiveness and potential adverse effects, including movement disorders. AIMS The aim of this study was to examine the prevalence of movement disorders (dyskinesia, akathisia, dystonia,(More)
A recent study showed that prescribing antipsychotics to mentally disabled patients with aggressive behavioural disorders is not effective. However, prevalence of antipsychotics use is high in this group because non-pharmacological treatments are often unavailable; establishing a diagnosis is very complex and there is often peer pressure to prescribe drugs.(More)
Psychotropic drugs are a cornerstone in the treatment of psychopathology and/or behavioral problems in children with intellectual disability (ID), despite concerns about efficacy and safety. Studies on the prevalence of psychotropic drug use have mainly been focused on adults with ID or children without ID. Therefore the aim of this cross sectional study(More)
BACKGROUND Polypharmacy and chronic drug use are common in people with intellectual disability and behavioural problems, although evidence of effectiveness and safety in this population is lacking. This study examined the effects of a structured medication review and aimed to improve pharmacotherapy in inpatients with intellectual disability. METHODS In a(More)
BACKGROUND Behavioural problems are common in people with intellectual disability (ID) and are often treated with antipsychotics. AIM To establish the frequency and characteristics of people with ID included in randomised controlled trials (RCTs) on antipsychotic treatment for behavioural problems, and to investigate the quality of these RCTs. METHODS A(More)
  • 1